Corvus Pharmaceuticals

$3.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-2.79%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CRVS and other stocks, options, and ETFs commission-free!

About CRVS

Corvus Pharmaceuticals, Inc. Common Stock, also called Corvus Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA. The listed name for CRVS is Corvus Pharmaceuticals, Inc. Common Stock.

CEO
Richard A. Miller
Employees
53
Headquarters
Burlingame, California
Founded
2014
Market Cap
148.63M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
3.10M
High Today
$3.68
Low Today
$3.31
Open Price
$3.58
Volume
1.74M
52 Week High
$6.88
52 Week Low
$1.01

CRVS Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 12, After Hours

You May Also Like

NWSA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure